SCHEMBL3847348

SCHEMBL3847348

O=c1cc(-c2ccncc2)[nH]c(Nc2ccc3cn[nH]c3c2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BUB1 O43683 2/20 0.49
EIF2AK2 P19525 1/20 0.49
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 3/20 0.44
MAPT P10636 3/20 0.44
MAPK1 P28482 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
HTT P42858 1/20 0.44
MCL1 Q07820 1/20 0.44
ATM Q13315 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAP3K11 Q16584 1/20 0.43
ALDH1A1 P00352 3/20 0.41
HSD17B10 Q99714 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14514008 0.81 BUB1 (0.49) BUB1EIF2AK2KMT2AKDM4EMAPT
SCHEMBL3825068 0.81 PIK3C3 (0.44) MAPK1NPC1CDC7CLK1CLK2
SCHEMBL3827756 0.77 PIK3C3 (0.53) BUB1KMT2ACDC7MEN1GAA
SCHEMBL5400013 0.75 NCOA1 (0.53) BUB1KMT2ARAB9ANPC1CDC7
SCHEMBL5380284 0.75 GCGR (0.44) BUB1KMT2AMAPTRAB9ANPC1
SCHEMBL3832211 0.74 CA1 (0.54) BUB1KMT2ANPC1MEN1ROCK2
SCHEMBL3827923 0.72 AKR1C3 (0.54) KMT2AKDM4ETDP1RAB9ANPC1
SCHEMBL3830998 0.72 MEN1 (0.54) BUB1KMT2AMAPTMAPK1RAB9A
SCHEMBL5632242 0.71 BUB1 (0.49) BUB1KMT2AKDM4EMAPTMAPK1
SCHEMBL3825878 0.71 ROCK2 (0.48) BRAFROCK2CDK1SRCCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713793-A4 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-09-02 EP claimed
US-20070117818-A1 Pyrimidinone compounds useful as kinase inhibitors HASEGAWA MASAICHI 2007-05-24 US claimed
EP-1713793-A2 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS Smithkline Beecham Corporation (US) 2006-10-25 EP claimed
WO-2005076854-A2 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO claimed
US-20070117818-A1 Pyrimidinone compounds useful as kinase inhibitors HASEGAWA MASAICHI 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117818-A1 Pyrimidinone compounds useful as kinase inhibitors HIPK3, HIPK1, HIPK2 BUB1 93/4885EIF2AK2 234/4885KMT2A 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.